Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment

Although lower-grade gliomas are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene and are less aggressive than primary glioblastoma, they nonetheless generally recur. IDH1 mutant patients are increasingly being treated with temozolomide (TMZ), but early detection of response remains...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Res
Main Authors: Subramani, Elavarasan, Radoul, Marina, Najac, Chloe, Batsios, Georgios, Molloy, Abigail R., Hong, Donghyun, Gillespie, Anne Marie, Santos, Romelyn Delos, Viswanath, Pavithra, Costello, Joseph F., Pieper, Russell O., Ronen, Sabrina M.
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7669718/
https://ncbi.nlm.nih.gov/pubmed/32958546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-1314
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker